486 related articles for article (PubMed ID: 19673980)
1. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.
Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D
Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980
[TBL] [Abstract][Full Text] [Related]
2. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.
Holle JU; Dubrau C; Herlyn K; Heller M; Ambrosch P; Noelle B; Reinhold-Keller E; Gross WL
Ann Rheum Dis; 2012 Mar; 71(3):327-33. PubMed ID: 22021864
[TBL] [Abstract][Full Text] [Related]
4. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.
Lovric S; Erdbruegger U; Kümpers P; Woywodt A; Koenecke C; Wedemeyer H; Haller H; Haubitz M
Nephrol Dial Transplant; 2009 Jan; 24(1):179-85. PubMed ID: 18685144
[TBL] [Abstract][Full Text] [Related]
5. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.
Keogh KA; Wylam ME; Stone JH; Specks U
Arthritis Rheum; 2005 Jan; 52(1):262-8. PubMed ID: 15641078
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations.
Seo P; Specks U; Keogh KA
J Rheumatol; 2008 Oct; 35(10):2017-23. PubMed ID: 18688911
[TBL] [Abstract][Full Text] [Related]
7. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis.
Taylor SR; Salama AD; Joshi L; Pusey CD; Lightman SL
Arthritis Rheum; 2009 May; 60(5):1540-7. PubMed ID: 19404964
[TBL] [Abstract][Full Text] [Related]
8. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis.
Koldingsnes W; Nossent JC
J Rheumatol; 2003 Jan; 30(1):80-8. PubMed ID: 12508394
[TBL] [Abstract][Full Text] [Related]
9. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.
Cartin-Ceba R; Golbin JM; Keogh KA; Peikert T; Sánchez-Menéndez M; Ytterberg SR; Fervenza FC; Specks U
Arthritis Rheum; 2012 Nov; 64(11):3770-8. PubMed ID: 22730028
[TBL] [Abstract][Full Text] [Related]
11. Etanercept plus standard therapy for Wegener's granulomatosis.
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group
N Engl J Med; 2005 Jan; 352(4):351-61. PubMed ID: 15673801
[TBL] [Abstract][Full Text] [Related]
12. [Experience with rituximab treatment (monoclonal antibodies to B-lymphocyte CD20 receptors) of Wegener's granulomatosis patients with renal impairment].
Novikov PI; Krivosheev OG; Semenkova EN
Ter Arkh; 2011; 83(11):70-6. PubMed ID: 22312891
[TBL] [Abstract][Full Text] [Related]
13. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
Pagnoux C; Mahr A; Hamidou MA; Boffa JJ; Ruivard M; Ducroix JP; Kyndt X; Lifermann F; Papo T; Lambert M; Le Noach J; Khellaf M; Merrien D; Puéchal X; Vinzio S; Cohen P; Mouthon L; Cordier JF; Guillevin L;
N Engl J Med; 2008 Dec; 359(26):2790-803. PubMed ID: 19109574
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological characteristics and outcomes of Chinese patients with primary anti-neutrophil cytoplasmic antibodies-associated systemic vasculitis with immune complex deposition in kidney.
Yu F; Chen M; Wang SX; Zou WZ; Zhao MH; Wang HY
Nephrology (Carlton); 2007 Feb; 12(1):74-80. PubMed ID: 17295665
[TBL] [Abstract][Full Text] [Related]
15. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
16. [Wegener's granulomatosis and microscopic polyangiitis].
Pagnoux C
Rev Prat; 2008 Mar; 58(5):522-32. PubMed ID: 18524109
[TBL] [Abstract][Full Text] [Related]
17. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
Eriksson P
J Intern Med; 2005 Jun; 257(6):540-8. PubMed ID: 15910558
[TBL] [Abstract][Full Text] [Related]
18. [Severe Wegener's granulomatosis successfully treated with rituximab].
Semenkova EN; Krivosheev OG; Novikov PI; Osipenko VI; Nosova NR; Parfenova SA; Nikiforova NV; Borodin OO
Ter Arkh; 2010; 82(6):53-5. PubMed ID: 20731113
[TBL] [Abstract][Full Text] [Related]
19. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
Popa C; Leandro MJ; Cambridge G; Edwards JC
Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244
[TBL] [Abstract][Full Text] [Related]
20. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
Pullerits R; Ljevak M; Vikgren J; Bokarewa M
Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
